Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis
PeerJ2020Vol. 8, pp. e8575–e8575
Citations Over TimeTop 19% of 2020 papers
Abstract
The combination therapy of olmesartan plus temocapril appeared to be the most efficacious for reducing proteinuria in normotensive CKD patients and IgA nephropathy, but the clinical application should be balanced against potential harms. Temocapril can be an option when practitioners are searching for more proteinuria reduction but less blood pressure variation. In normotensive diabetic nephropathy, monotherapy with the ACEI enalapril seems to be the most efficacious intervention for reducing albuminuria. Future studies are required to give a more definitive recommendation.
Related Papers
- → Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?(2000)16 cited
- → Anti-Inflammatory Action of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers(2006)1 cited
- → Potential for Optimizing Beta Blocker and Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blockers Use in Patients with Moderate to Severe Left Ventricular Dysfunction(2008)
- Progess in Preventing Arrhythmias by Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers(2006)
- → Assessment of adverse drug reactions of angiotensin converting enzyme (ace) inhibitors and angiotensin receptor blockers (arbs) among sudanese patients(2017)